Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years

Long-term data on ustekinumab in real-life Crohn’s disease patients are still missing, though randomized controlled trials demonstrated it as a favorable therapeutic option. We aimed to evaluate ustekinumab's clinical efficacy, drug sustainability, and safety in a prospective, nationwide, multi...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Barkai László József
Gönczi Lóránt
Balogh Fruzsina
Angyal Dorottya
Farkas Klaudia
Farkas Bernadett
Molnár Tamás
Szamosi Tamas
Schafer Eszter
Golovics Petra A.
Juhasz Mark
Patai Arpad
Vincze Áron
Sarlós Patrícia
Farkas Alexandra
Dubravcsik Zsolt
Toth Tamas G.
Székely Hajnal
Miheller Pál
Lakatos Péter László
Iliás Ákos
Dokumentumtípus: Cikk
Megjelent: 2024
Sorozat:SCIENTIFIC REPORTS 14 No. 1
Tárgyszavak:
doi:10.1038/s41598-024-65987-1

mtmt:35077701
Online Access:http://publicatio.bibl.u-szeged.hu/34398
LEADER 03205nab a2200457 i 4500
001 publ34398
005 20240729152555.0
008 240729s2024 hu o 000 eng d
022 |a 2045-2322 
024 7 |a 10.1038/s41598-024-65987-1  |2 doi 
024 7 |a 35077701  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a eng 
100 1 |a Barkai László József 
245 1 0 |a Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years  |h [elektronikus dokumentum] /  |c  Barkai László József 
260 |c 2024 
300 |a 8 
490 0 |a SCIENTIFIC REPORTS  |v 14 No. 1 
520 3 |a Long-term data on ustekinumab in real-life Crohn’s disease patients are still missing, though randomized controlled trials demonstrated it as a favorable therapeutic option. We aimed to evaluate ustekinumab's clinical efficacy, drug sustainability, and safety in a prospective, nationwide, multicenter Crohn’s disease patient cohort with a three-year follow-up. Crohn’s disease patients on ustekinumab treatment were consecutively enrolled from 9 Hungarian Inflammatory Bowel Disease centers between January 2019 and May 2020. Patient and disease characteristics, treatment history, clinical disease activity (Harvey Bradshaw Index (HBI)), biomarkers, and endoscopic activity (Simple Endoscopic Score for Crohn’s Disease (SES-CD)) were collected for three-years’ time. A total of 148 patients were included with an overall 48.9% of complex behavior of the Crohn’s disease and 97.2% of previous anti-TNF exposure. The pre-induction remission rates were 12.2% (HBI), and 5.1% (SES-CD). Clinical remission rates (HBI) were 52.2%, 55.6%, and 50.9%, whereas criteria of an endoscopic remission were fulfilled in 14.3%, 27.5%, and 35.3% of the subjects at the end of the first, second, and third year, respectively. Dose intensification was high with 84.0% of the patients on an 8-weekly and 29.9% on a 4-weekly regimen at the end of year 3. Drug sustainability was 76.9% during the follow-up period with no serious adverse events observed. Ustekinumab in the long-term is an effective, sustainable, and safe therapeutic option for Crohn’s disease patients with severe disease phenotype and high previous anti-TNF biological failure, requiring frequent dose intensifications. 
650 4 |a Gasztroenterológia és hepatológia 
700 0 1 |a Gönczi Lóránt  |e aut 
700 0 1 |a Balogh Fruzsina  |e aut 
700 0 1 |a Angyal Dorottya  |e aut 
700 0 1 |a Farkas Klaudia  |e aut 
700 0 1 |a Farkas Bernadett  |e aut 
700 0 1 |a Molnár Tamás  |e aut 
700 0 1 |a Szamosi Tamas  |e aut 
700 0 1 |a Schafer Eszter  |e aut 
700 0 1 |a Golovics Petra A.  |e aut 
700 0 1 |a Juhasz Mark  |e aut 
700 0 1 |a Patai Arpad  |e aut 
700 0 1 |a Vincze Áron  |e aut 
700 0 1 |a Sarlós Patrícia  |e aut 
700 0 1 |a Farkas Alexandra  |e aut 
700 0 1 |a Dubravcsik Zsolt  |e aut 
700 0 1 |a Toth Tamas G.  |e aut 
700 0 1 |a Székely Hajnal  |e aut 
700 0 1 |a Miheller Pál  |e aut 
700 0 1 |a Lakatos Péter László  |e aut 
700 0 1 |a Iliás Ákos  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/34398/1/s41598-024-65987-1.pdf  |z Dokumentum-elérés